This article is more than 5 years old. Information may no longer be current.

Intravitreal steroids can raise IOP

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — The prevalence of IOP increase after intravitreal steroid injection is greater than has been previously reported, according to a presenter here. Douglas J. Rhee, MD, spoke about his findings here at the American Academy of Ophthalmology meeting.

Dr. Rhee and colleagues reviewed results in 324 eyes with at least 6-month follow-up after receiving injections of intravitreal Kenalog (triamcinolone acetonide, Bristol-Myers Squibb) to determine the prevalence of clinically significant IOP elevations. Triamcinolone is currently being investigated as a treatment for diabetic macular edema, Dr. Rhee said.

The researchers found that 48% of the eyes developed a “significant” IOP elevation, defined as more than 5 mm Hg, he said. Moreover, 35% of those patients had an IOP increase of more than 10 mm Hg. Among the eyes with elevated IOP, 42% had the initial elevation within 1 month, while 17% were seen at 6 months.

“There were a large number of subjects with repeat injections,” Dr. Rhee said.